Table 2.
Patient and tumor characteristics of 108 patients with newly diagnosed glioblastoma stratified by p-MAPK expression
| All cases | pMAPK expression levels |
||||
|---|---|---|---|---|---|
| ≤10 | 10–40 | >40 | |||
| Characteristics | n | n (%) | n (%) | n (%) | P value |
| Total cases | 108 | 33 | 37 | 38 | |
| Age | |||||
| Median | 65 | 67 | 63 | 64 | .58 |
| Range | 18–92 | 31–85 | 37–88 | 18–92 | |
| Gender | .29 | ||||
| Female | 39 (36.1) | 11 (33.3) | 17 (46.0) | 11 (29.0) | |
| Male | 69 (63.9) | 22 (66.7) | 20 (54.0) | 27 (71.0) | |
| Tumor Location | .52 | ||||
| Infratentorial | 1 (0.9) | 1 (3.0) | 0 | 0 | |
| Supratentorial | 106 (98.2) | 32 (97.0) | 37 (100) | 37 (97.4) | |
| Both | 1 (0.9) | 0 (0) | 0 | 1 (2.6) | |
| Karnofsky Performance Status | .35 | ||||
| 80–100 (normal activity) | 80 (74.1) | 26 (78.8) | 29 (78.4) | 25 (65.8) | |
| 50–70 (requires assistance) | 24 (22.2) | 5 (15.2) | 8 (21.6) | 11(28.9) | |
| ≤40 (disabled) | 4 (3.7) | 2 (6.1) | 0 | 2 (5.3) | |
| Extent of Resection | .38 | ||||
| biopsy | 24 (22.6) | 9 (28.1) | 6 (16.2) | 9 (24.3) | |
| partial resection | 25 (23.6) | 7 (21.9) | 8 (21.6) | 10 (27.0) | |
| near gross-total resection | 18 (17.0) | 2 (6.3) | 8 (21.6) | 8 (21.6) | |
| gross-total resection | 39 (36.8) | 14 (43.8) | 15 (40.5) | 10 (27.0) | |
| EGFR Expression | .67 | ||||
| normal | 34 (37.4) | 13 (43.3) | 9 (32.1) | 12 (36.4) | |
| abnormal | 57 (62.6) | 17 (56.7) | 19 (67.9) | 21 (63.6) | |
| MGMT Immunohistochemical Expression | .02 | ||||
| ≥20% | 40 (37.0) | 6 (18.8) | 22 (59.5) | 19 (50.0) | |
| <20% | 68 (63.0) | 26 (81.2) | 15 (40.5) | 19 (50.0) | |
| PTEN Expression | .32 | ||||
| loss | 58 (56.9) | 21 (36.2) | 19 (32.8) | 18 (31.0) | |
| retained | 44 (43.1) | 10 (22.7) | 16 (36.4) | 18 (40.9) | |
| Standard Treatment* | .02 | ||||
| yes | 72 (79.1) | 29 (87.9) | 31 (83.8) | 29 (76.3) | |
| no | 19 (20.9) | 4 (12.1) | 6 (16.2) | 9 (23.7) | |
*Standard treatment = Temozolomide and radiation.
EGFR/PTEN expression data available in 91/102 patients.